BSRC will report its 1Q25 results on 7 May 25, where we expect a slim net profit of Bt150m and a modest core profit of Bt230m. We foresee opportunities to accumulate the stock due to a more favourable swap ratio to BCP, following BCP shareholders’ approval of the restructuring plan and the acquisition of the remaining BSRC shares. Maintain BUY. Target price: Bt7.00.
KEY HIGHLIGHTS Results Home Product Center (HMPRO TB/HOLD/Bt8.25/Target: Bt10.00) 1Q25: Flattish yoy earnings momentum. Update Bangchak Corporation (BCP TB/BUY/Bt35.50/Target: Bt45.00) 1Q25 results preview: Expect a soft quarter, but remain positive on the long-term outlook. Bangchak Sriracha (BSRC TB/BUY/Bt5.35/Target: Bt7.00) 1Q25 results preview: Expect slim core and net profits. SCG Packaging (SCGP TB/HOLD/Bt14.00/Target: Bt13.20) 2Q25 net profit expected to contin...
GREATER CHINA Results China Construction Bank (939 HK/HOLD/HK$6.79/Target: HK$7.00): 1Q25: Earnings miss due to weaker NIM and fee income; tariff risk is limited. Downgrade to HOLD. China Longyuan Power (916 HK/HOLD/HK$6.10/Target: HK$6.60): 1Q25: In line; cautious outlook amid rising curtailment rates and upcoming policy shift. China Merchants Bank (3968 HK/BUY/HK$44.50/Target: HK$49.00): 1Q25: Earnings down 2.1% yoy on weaker trading gains. Estun Automation (002747 CH/SELL/Rmb19.17/Target: Rmb...
BSRC posted a 4Q24 net loss of Bt1.0b, narrowing from a loss of Bt1.7b in 3Q24 and loss of Bt2.0b in 4Q23. Excluding one-off items, BSRC’s core profit was Bt459m (3Q24: Bt75m gain; 4Q23: Bt192m loss). Core profit for 2004 totalled Bt1.5b, down 74% yoy. Both core and net profits are in line with our estimate. We expect BSRC to make a turnaround to a profit of Bt3.9b. It is trading near -2.0SD, which offers an attractive dividend yield of 4.8% in 2025. Maintain BUY. Target price: Bt8.00.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt36.50/Target: Bt45.00) 4Q24: Above expectations; earnings projected to outperform peers’ in 2025. Bangchak Sriracha (BSRC TB/BUY/Bt4.94/Target: Bt8.00) 4Q24: Results in line with expectations. GFPT (GFPT TB/BUY/Bt9.15/Target: Bt13.00) 4Q24: Earnings miss expectations; deep discount valuation. True Corporation (TRUE TB/BUY/Bt12.80/Target: Bt14.50) 4Q24: Results below our...
BSRC will report its 4Q24 results on 19 Feb 25 where we expect a net loss of Bt994m. This would bring its 2024 net loss to Bt1.7b. However, excluding extra items, BSRC’s core profit could surge 787% qoq to Bt664m in 4Q24, contributing to a core profit of Bt1.6b for 2024. We foresee opportunities to accumulate the stock after share price tumbled 33% ytd. Maintain BUY. Target price: Bt8.00.
GREATER CHINA Strategy Small-Mid Cap Monthly: Countdown to Plover Bay’s 2024 results: Eyeing final dividend and 2025 outlook. Sector Automobile: Weekly: OEMs post upbeat January sales. Maintain MARKET WEIGHT. Top BUYs: Geely, CATL, Fuyao and Desay. Update Aier Eye Hospital Group (300015 CH/HOLD/Rmb12.71/Target: Rmb13.80): Expecting slower growth amid weaker demand, yet outperforming peers. Downgrade to HOLD. INDONESIA Results XL Axiata (EXCL IJ/BUY/Rp2,290/Target: Rp3,300): 4Q24: NPAT jumps 93%...
GREATER CHINA Strategy Alpha Picks: December Conviction Calls Add Desay, Meituan, Mengniu, Tencent, and Trip.com to our BUY list. Take profit from CATL. Update CR Mixc Lifestyle (1209 HK/BUY/HK$29.20/Target: HK$32.15) Takeaways from reverse roadshow in Shenzhen. China Resources Land (1109 HK/BUY/HK$23.25/Target:HK$32.40) Takeaways from reverse roadshow in Shenzhen. Small/Mid Cap Highlights Regina Miracle (2199 HK/Not Rated/HK$2....
BSRC reported a net loss of Bt1.7b in 3Q24, reversing from net profits of Bt221m in 2Q24 and Bt3.5b in 3Q23, due to a huge inventory loss of Bt2.8b. Excluding one-off items, BSRC would have reported a slim core profit of Bt75m, turning from a core loss of Bt28m in 2Q24. We believe BSRC’s operating performance will continue to improve in 4Q24 while its valuation is undemanding and also provides a yield of 6.3% in 2025. Maintain BUY. Target price: Bt9.00.
KEY HIGHLIGHTS Results Bangchak Corporation (BCP TB/BUY/Bt33.00/Target: Bt45.00) 3Q24: Earnings hurt by weaker GIM and inventory loss Bangchak Sriracha (BSRC TB/BUY/Bt7.10/Target: Bt9.00) 3Q24: Results better than expected. Berli Jucker (BJC TB/BUY/Bt23.40/Target: Bt28.00) 3Q24: Earnings in line; expect 4Q24 EBIT to continue to improve yoy. Bumrungrad Hospital (BH TB/BUY/Bt262.00/Target: Bt303.00) 3Q24: Di...
GREATER CHINA Strategy Alpha Picks: September Conviction Calls: We expect an improving operating performance among selected companies in September, and add AIA, COLI, Desay SV, Galaxy Entertainment, Meituan, Ping An and TUL to our BUY list and add Li Auto as a SELL. INDONESIA Strategy Alpha Picks: Trailing The JCI’s Strong Performance In Aug 24: Our picks are ICBP, TOWR, BBNI, BMRI, BBRI, EXCL, CTRA, BBTN, CMRY, SIDO and JSMR. MALAYSIA Strategy Alpha Picks: Adapting To A Bipolar Market: Our Al...
GREATER CHINA Strategy Alpha Picks: August Conviction Calls: We expect stimulus to be announced in August and add COSCO Shipping Ports, Haier Smart Home, and KE Holdings to our BUY list and add SELL call on WuXi Bio, and XPeng. INDONESIA Strategy Alpha Picks: Underperformance in Jul 24: Our picks are BBNI, BMRI, BBRI, EXCL, CTRA, BBTN, CMRY, SIDO and JSMR. MALAYSIA Strategy Alpha Picks: Raising The M&A And Monetisation Bets: Our Alpha Picks marginally beat the KLCI. Jul 24 picks: Ekovest, Gamu...
GREATER CHINA Economics Economic Activity 2Q24 growth below expectations. Strategy China And Hong Kong Property Sharper property price decline in 1H24 weighing on margins of Chinese developers; upcoming interest rate cut to support value of Hong Kong retail landlords. Update Kingmed Diagnostics (603882 CH/BUY/Rmb38.10/Target: Rmb35.00) 1H24 and 2024 results under pressu...
GREATER CHINA Strategy Alpha Picks: July Conviction Call: Adding ASMPT, Innovent, Poly Property Services, TAL Education and Trip.com to our BUY list; hedging with SELL call on BYD. INDONESIA Strategy Alpha Picks: Outperformance In Jun 24 And 2Q24: Our picks are BMRI, BBRI, EXCL, BSDE, TLKM, ACES, BBTN, CMRY, SIDO and JSMR. MALAYSIA Strategy Alpha Picks: Opting For More Adventurous Choices: Our Alpha Picks beat the KLCI again. Jul 24 picks: BURSA, Ekovest, Gamuda, Lagenda, Mah Sing, MYEG, Pekat...
GREATER CHINA Strategy Alpha Picks: June Conviction Call: Adding KE Holdings and Wharf REIC to our BUY list; hedging with SELL call on BYD. INDONESIA Strategy Alpha Picks: First Month Of Underperformance In 2024: Our picks are EXCL, BSDE, TLKM, ACES, BBTN, CMRY, SIDO and JSMR. MALAYSIA Strategy Alpha Picks: Choices For A “Summer Lull”: Our Alpha Picks trounce the KLCI again. May 24 picks: BAUTO, BURSA, Gamuda, GENM, Lagenda, Mah Sing, MYEG, PMETAL, RGB, and VSI. SINGAPORE Strategy Alpha Picks...
GREATER CHINA Strategy Alpha Picks: May Conviction Call: Adding CR Beer, Crystal, Geely, Haier, Kuaishou, Ningbo Tuopu, Pinduoduo, Shenzhou, and Tencent to our BUY list, closing out SELL calls. INDONESIA Strategy Alpha Picks: Slight Outperformance In A Bear Market: Our picks are BSDE, TLKM, ACES, BBTN, CMRY, SIDO, JSMR and AKRA. MALAYSIA Strategy Alpha Picks: Well-Positioned For 1Q Results Season: Our April picks again beat the KLCI. May 24 picks: GENM, Inari, Mah Sing, MrDIY, MYEG, Press Meta...
GREATER CHINA Strategy Alpha Picks: April Conviction Calls: Adding AIA, Midea, Hansoh Pharmaceutical, Shenzhen Inovance and Trip.com to our BUY list, with SELL calls on BYD, EVE Energy, and Li Auto. INDONESIA Strategy Alpha Picks: Outperformance In Mar 24 and 1Q24: Our picks are ACES, BBTN, CMRY, SIDO, EXCL, MAPI, JSMR, CTRA, and AKRA. MALAYSIA Strategy Alpha Picks: Expanding The Variety Of Events Bets: Our Alpha Picks trounced the KLCI in Mar 24. Apr 24 picks: GENM, Inari, Mah Sing, MrDIY, MY...
GREATER CHINA Strategy Small-Mid Cap Biweekly: Eyeing PCB recovery. Update BYD Company (1211 HK/SELL/HK$222.20/Target: HK$140.00): Downgrade from BUY to SELL on peaking retail sales and piling inventories. Slash target price from HK$630.00 to HK$140.00. Innovent Biologics (1801 HK/BUY/HK$45.30/Target: HK$60.00): Smooth progress in drug sales and R&D, targeting revenue of Rmb20b in 2027. INDONESIA Sector Coal: Flattish demand outlook with stabilising prices, dividend yield remains attractive. Do...
ESSO reported a net profit of Bt4.6b for 3Q23, reversing from a loss of Bt1.3b in 2Q23 and a loss of Bt3.1b in 3Q22. Excluding an inventory gain of Bt2.7b, ESSO’s core profit rose by 84% yoy and 545% qoq to Bt2.5b, exceeding our estimate by 100% due to higher-than-expected market GRM. Despite a lower GRM outlook, we expect ESSO to maintain its core earnings at a breakeven level in 4Q23. We also expect profit to remain solid in 2024 with a dividend yield of 8.4%. Maintain BUY. Target price: Bt15....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.